基于TCGA数据库的AIM2在结直肠癌中的表达分析及临床相关性研究
|
摘要
目的:通过独立公开的TCGA数据库资源,探讨黑色素瘤缺乏因子2(AIM2)的表达与结直肠癌患者临床病理特征的相关性。方法:TCGA数据平台(https://portal. gdc. cancer. gov/)下载结直肠癌组织和正常组织AIM2基因表达数据及相关临床数据,并分析其表达与临床病理特征的关系。结果:癌组织中AIM2的表达显著低于正常对照组(P=0. 001 3),且正常对照组中AIM2的表达显著高于任何T分期、任何N分期以及任何M分期患者的癌组织(P <0. 000 1);癌组织中AIM2的表达与患者年龄、性别、肿瘤位置、T分期、N分期、M分期和病理分期均无明显相关(P> 0. 05),与患者5年总生存期无明显相关(P=0. 418 0); II期患者癌组织中AIM2的表达显著高于IV期患者(P=0. 023 7)。结论:结直肠癌组织中AIM2的表达显著低于正常组织,但与患者T分期、N分期、M分期和患者5年总生存期无明显相关,II期患者癌组织中AIM2的表达显著高于IV期患者,因此,AIM2的表达可能主要参与结直肠癌发生的早期过程。该结论仍需通过更多的研究进行验证。
Objective: To investigate the association between absent in melanoma 2( AIM2) expression and clinicopathological variables in colorectal cancer( CRC) based on TCGA data. Methods: Data about AIM2 gene expression in CRC was downloaded from TCGA platform( https://portal. gdc. cancer. gov/). Correlation between AIM2 expression and clinicopathological variables was analyzed. Results: Expression level of AIM2 in CRC was significantly lower than in normal control( P = 0. 001 3),also higher expression of AIM2 was observed in normal control than in cancer cases with any T stage,N stage and M stage( P < 0. 000 1). AIM2 expression had no correlation with gender,age,tumor location,T stage,N stage,M stage,pathological stage and 5-year overall survival rates( 5-OS),but higher expression of AIM2 was observed in stage II than in stage IV( P = 0. 023 7). Conclusion: The expression level of AIM2 in cancer cases is lower than in normal control,but has no relation with clinicopathological variables and 5-OS in CRC,but the expression level of AIM2 is higher in stage II than in stage IV. So,the expression of AIM2 might be involved in the early course of colorectal cancer. Further studies are warranted to confirm this conclusion.
Objective: To investigate the association between absent in melanoma 2( AIM2) expression and clinicopathological variables in colorectal cancer( CRC) based on TCGA data. Methods: Data about AIM2 gene expression in CRC was downloaded from TCGA platform( https://portal. gdc. cancer. gov/). Correlation between AIM2 expression and clinicopathological variables was analyzed. Results: Expression level of AIM2 in CRC was significantly lower than in normal control( P = 0. 001 3),also higher expression of AIM2 was observed in normal control than in cancer cases with any T stage,N stage and M stage( P < 0. 000 1). AIM2 expression had no correlation with gender,age,tumor location,T stage,N stage,M stage,pathological stage and 5-year overall survival rates( 5-OS),but higher expression of AIM2 was observed in stage II than in stage IV( P = 0. 023 7). Conclusion: The expression level of AIM2 in cancer cases is lower than in normal control,but has no relation with clinicopathological variables and 5-OS in CRC,but the expression level of AIM2 is higher in stage II than in stage IV. So,the expression of AIM2 might be involved in the early course of colorectal cancer. Further studies are warranted to confirm this conclusion.
引文
[1] Hanahan D,Weinberg RA. Hallmarks of cancer:The next generation[J]. Cell,2011,144(5):646-674.
[2] Long AG,Lundsmith ET,Hamilton KE. Inflammation and colorectal cancer[J]. Curr Colorectal Cancer Rep,2017,13(4):341-351.
[3] Martinon F,Burns K,Tschopp J. The inflammasome:A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta[J]. Mol Cell,2002,10(2):417-426.
[4] Rathinam VA,Fitzgerald KA. Inflammasome complexes:Emerging mechanisms and effector functions[J]. Cell,2016,165(4):792-800.
[5] W Vanhove,PM Peeters,D Staelens,et al. Strong upregulation of AIM2 and IFI16 inflammasomes in the mucosa of patients with active inflammatory bowel disease[J]. Inflamm Bowel Dis,2015,21(11):2673-2682.
[6] JE Wilson,AS Petrucelli,L Chen,et al. Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt[J]. Nat Med,2015,21(8):906-913.
[7] J Lugrin,F Martinon. The AIM2 inflammasome:Sensor of pathogens and cellular perturbations[J]. Immunol Rev,2018,281(1):99-114.
[8] KL De Young,ME Ray,YA Su,et al. Trent,cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma[J]. Oncogene,1997,15(4):453-457.
[9] R Karki,SM Man,TD Kanneganti. Inflammasomes and cancer[J].Cancer Immunol Res,2017,5(2):94-99.
[10] RA Ratsimandresy,M Indramohan,A Dorfleutner,et al. The AIM2inflammasome is a central regulator of intestinal homeostasis through the IL-18/IL-22/STAT3 pathway[J]. Cell Mol Immunol,2017,14(1):127-142.
[11] S Dihlmann,S Tao,F Echterdiek,et al. Lack of absent in melanoma 2(AIM2)expression in tumor cells is closely associated with poor survival in colorectal cancer patients[J]. Int J Cancer,2014,135(10):2387-2396.
[12] Z Zhang,X Dong,X Yang,et al. Expression and clinical significance of absent in melanoma 2 in colorectal cancer[J]. Biomed Pharmacother,2017,94:843-849.
[13] Yang HQ,Wang K. The research about expression of absent in melanoma 2(AIM2)in tumor tissues of patients with colorectal cancer and correlation with clinical and pathological outcomes[D]. Southwest Medical University,2017:1-50.[杨虎强,王康.结直肠癌手术患者肿瘤组织中AIM2表达情况及其与临床病理资料的相关性研究[D].西南医科大学,2017:1-50.]
[14] Chen JJ,Wang ZJ. Expression of AIM2 in colorectal cancer and its role and mechanism of proliferation and apoptosis[D]. Capital Medical University,2017:1-101.[陈建军,王振军. AIM2在结直肠癌中的表达与对增殖及凋亡的作用和机制研究[D].首都医科大学,2017:1-101.]
[15] R Liu,AD Truax,L Chen,et al. Expression profile of innate immune receptors,NLRs and AIM2,in human colorectal cancer:Correlation with cancer stages and inflammasome components[J].Oncotarget,2015,6(32):33456-33469.
[16] BM Inouye,FM Hughes Jr,SJ Sexton,et al. The emerging role of inflammasomes as central mediators in inflammatory bladder pathology[J]. Curr Urol,2018,11(2):57-72.
[17] NB Janakiram,CV Rao. The role of inflammation in colon cancer[J]. Adv Exp Med Biol,2014,81:25-52.
[18] J Chen,Z Wang,S Yu. AIM2 regulates viability and apoptosis in human colorectal cancer cells via the PI3K/Akt pathway[J]. Onco Targets Ther,2017,10:811-817.
[2] Long AG,Lundsmith ET,Hamilton KE. Inflammation and colorectal cancer[J]. Curr Colorectal Cancer Rep,2017,13(4):341-351.
[3] Martinon F,Burns K,Tschopp J. The inflammasome:A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta[J]. Mol Cell,2002,10(2):417-426.
[4] Rathinam VA,Fitzgerald KA. Inflammasome complexes:Emerging mechanisms and effector functions[J]. Cell,2016,165(4):792-800.
[5] W Vanhove,PM Peeters,D Staelens,et al. Strong upregulation of AIM2 and IFI16 inflammasomes in the mucosa of patients with active inflammatory bowel disease[J]. Inflamm Bowel Dis,2015,21(11):2673-2682.
[6] JE Wilson,AS Petrucelli,L Chen,et al. Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt[J]. Nat Med,2015,21(8):906-913.
[7] J Lugrin,F Martinon. The AIM2 inflammasome:Sensor of pathogens and cellular perturbations[J]. Immunol Rev,2018,281(1):99-114.
[8] KL De Young,ME Ray,YA Su,et al. Trent,cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma[J]. Oncogene,1997,15(4):453-457.
[9] R Karki,SM Man,TD Kanneganti. Inflammasomes and cancer[J].Cancer Immunol Res,2017,5(2):94-99.
[10] RA Ratsimandresy,M Indramohan,A Dorfleutner,et al. The AIM2inflammasome is a central regulator of intestinal homeostasis through the IL-18/IL-22/STAT3 pathway[J]. Cell Mol Immunol,2017,14(1):127-142.
[11] S Dihlmann,S Tao,F Echterdiek,et al. Lack of absent in melanoma 2(AIM2)expression in tumor cells is closely associated with poor survival in colorectal cancer patients[J]. Int J Cancer,2014,135(10):2387-2396.
[12] Z Zhang,X Dong,X Yang,et al. Expression and clinical significance of absent in melanoma 2 in colorectal cancer[J]. Biomed Pharmacother,2017,94:843-849.
[13] Yang HQ,Wang K. The research about expression of absent in melanoma 2(AIM2)in tumor tissues of patients with colorectal cancer and correlation with clinical and pathological outcomes[D]. Southwest Medical University,2017:1-50.[杨虎强,王康.结直肠癌手术患者肿瘤组织中AIM2表达情况及其与临床病理资料的相关性研究[D].西南医科大学,2017:1-50.]
[14] Chen JJ,Wang ZJ. Expression of AIM2 in colorectal cancer and its role and mechanism of proliferation and apoptosis[D]. Capital Medical University,2017:1-101.[陈建军,王振军. AIM2在结直肠癌中的表达与对增殖及凋亡的作用和机制研究[D].首都医科大学,2017:1-101.]
[15] R Liu,AD Truax,L Chen,et al. Expression profile of innate immune receptors,NLRs and AIM2,in human colorectal cancer:Correlation with cancer stages and inflammasome components[J].Oncotarget,2015,6(32):33456-33469.
[16] BM Inouye,FM Hughes Jr,SJ Sexton,et al. The emerging role of inflammasomes as central mediators in inflammatory bladder pathology[J]. Curr Urol,2018,11(2):57-72.
[17] NB Janakiram,CV Rao. The role of inflammation in colon cancer[J]. Adv Exp Med Biol,2014,81:25-52.
[18] J Chen,Z Wang,S Yu. AIM2 regulates viability and apoptosis in human colorectal cancer cells via the PI3K/Akt pathway[J]. Onco Targets Ther,2017,10:811-817.